[{"Assets_0_Q2_USD":83155000.0,"CommonStockSharesOutstanding_0_Q2_shares":53388420.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-24074000.0,"NetIncomeLoss_1_Q2_USD":-19654000.0,"NetIncomeLoss_2_Q2_USD":-33789000.0,"StockholdersEquity_0_Q2_USD":51825000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1027000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2053000.0,"Ticker":"FATE","CIK":"1434316","name":"FATE THERAPEUTICS INC","OfficialName":"Fate Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3545646272.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180806"}]